| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5648670 | Journal of the American Academy of Dermatology | 2017 | 13 Pages |
Abstract
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Virginia O. MD, Daniel M. BS, Upendra MD, Jane M. MD,